Silver Book Fact

Assuming that Medicare Part D covers about 37% of beneficiaries’ drug costs, it is estimated that providing post-myocardial infarction Medicare beneficiaries with full coverage for combination pharmcotherapy will save more than $5,600 per patient over a 3-year period.

Choudhry, Niteesh, Jerry Avorn, Elliot M. Antman, Sebastian Schneeweiss, and William H. Shrank. Should Patients Receive Secondary Prevention Medications For Free After A Myocardial Infarction? An economic analysis. Health Affairs. 2007; 26(1): 186-194. https://www.healthaffairs.org/doi/abs/10.1377/hlthaff.26.1.186?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dpubmed

Reference

Title
Should Patients Receive Secondary Prevention Medications For Free After A Myocardial Infarction? An economic analysis
Publication
Health Affairs
Publisher
Project HOPE
Publication Date
2007
Authors
Choudhry, Niteesh, Jerry Avorn, Elliot M. Antman, Sebastian Schneeweiss, and William H. Shrank
Volume & Issue
Volume 26, Issue 1
Pages
186-194
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • t-PA cost savings
    The total annual benefit to society from t-PA use in the United States is around $363 million—$60 million in direct cost savings to society plus an additional 7,510 QALYs. This means…  
  • Initiating and continuing beta-blocker use in most first-time heart attack survivors for 20 years would result in 72,000 fewer coronary heart disease deaths, 62,000 fewer heart attacks, and 447,000 gained…  
  • A blood thinning drug was found to reduce the risk of heart attack, stroke, and cardiovascular disease by 20% in patients with acute coronary syndrome when given in addition to…  
  • Direct thrombin inhibitor reduced relative risk of venous thromboembolism
    An investigational direct thrombin inhibitor reduced relative risk of venous thromboembolism after total hip replacement surgery by 65.7%—compared to a currently available treatment.  
  • Primary angioplasty reduces 30-day mortality risk by 34% to 50%.